As a HIF2-α target rather than a HIF1-α target, PD-L1, which is upregulated in pVHL-deficient ccRCC, may be an additional choice for ccRCC treatment with the combination of PD-L1 and HIF inhibitors [98]. Here, VHL is linked to nonpapillary renal cell carcinoma.